京都大学大学院医学研究科 血液・腫瘍内科学

研究

ホーム ＞ 研究 ＞ 研究業績

研究業績（2022年1月－12月）

LIST OF PUBLICATIONS

英文

  1. Kogure Y, Kameda T, Koya J, Yoshimitsu M, Nosaka K, Yasunaga JI, Imaizumi Y, Watanabe M, Saito Y, Ito Y, McClure MB, Tabata M, Shingaki S, Yoshifuji K, Chiba K, Okada A, Kakiuchi N, Nannya Y, Kamiunten A, Tahira Y, Akizuki K, Sekine M, Shide K, Hidaka T, Kubuki Y, Kitanaka A, Hidaka M, Nakano N, Utsunomiya A, Sica RA, Acuna-Villaorduna A, Janakiram M, Shah UA, Ramos JC, Shibata T, Takeuchi K, Takaori-Kondo A, Miyazaki Y, Matsuoka M, Ishitsuka K, Shiraishi Y, Miyano S, Ogawa S, Ye BH, Shimoda K, Kataoka K. Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood. 139(7): 967-982, 2022.
  2. Shibata S, Inano S, Watanabe M, Fujiwara K, Ueno H, Nannya Y, Kanda J, Kawasaki N, Okamoto Y, Takiuchi Y, Fukunaga A, Tabata S, Ogawa S, Takaori-Kondo A, Kitano T. Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia. Int J Hematol. 115(3): 428-434, 2022.
  3. Kimura I, Kosugi Y, Wu J, Zahradnik J, Yamasoba D, Butlertanaka EP, Tanaka YL, Uriu K, Liu Y, Morizako N, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Ueno T, Takaori-Kondo A, Schreiber G, Arase H; Genotype to Phenotype Japan (G2P-Japan) Consortium, Motozono C, Saito A, Nakagawa S, Sato K. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. Cell Rep. 38(2): 110218, 2022.
  4. Ishii A, Jo T, Arai Y, Oshima S, Kanda J, Kitawaki T, Matsui K, Niwa N, Nakagawa Y, Takaori-Kondo A, Nagao M. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. Cytotherapy. 24(1): 49-58, 2022.
  5. Muranushi H, Kanda J, Kobayashi M, Maeda T, Kitano T, Tsuji M, Ueda Y, Ishikawa T, Nohgawa M, Watanabe M, Imada K, Moriguchi T, Itoh M, Ohno H, Yonezawa A, Hirata H, Arima N, Asagoe K, Anzai N, Nagata K, Yasuno S, Kuwabara Y, Kitao H, Kim I, Kawagishi K, Ueshima K, Tominari S, Nakayama T, Yamashita K, Takaori-Kondo A. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial. Hematology. 27(1): 239-248, 2022.
  6. Nishi K, Sakamaki T, Sadaoka K, Fujii M, Takaori-Kondo A, Chen JY, Miyanishi M. Identification of the minimum requirements for successful haematopoietic stem cell transplantation. Br J Haematol. 196(3): 711-723, 2022.
  7. Yuan H, Nishikori M, Ueda C, Fujimoto M, Yasumi T, Otsuka Y, Kitawaki T, Hirata M, Haga H, Kanegane H, Takaori-Kondo A. A sporadic case of CTLA4 haploinsufficiency manifesting as Epstein-Barr virus-positive diffuse large B-cell lymphoma. J Clin Exp Hematop. 62(1): 52-57, 2022.
  8. Morimoto Y, Chonabayashi K, Kawabata H, Okubo C, Yamasaki-Morita M, Nishikawa M, Narita M, Inagaki A, Nakanishi K, Nagao M, Takaori-Kondo A, Yoshida Y. Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia. Blood Adv. 6(4): 1100-1114, 2022.
  9. Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 602(7896): 300-306.2022.
  10. Nakamura N, Nishikori M, Tsujimura M, Kageyama Y, Akiyama D, Yoshizawa A, Takaori-Kondo A. Intravascular clusters of T cells following chimeric antigen receptor T cell therapy. eJHaem.3(2): 576-577, 2022.
  11. Morimoto S, Kondo T, Taya T, Matsuo H, Teramoto Y, Mizumoto C, Kanda J, Yamashita K, Takaori-Kondo A. Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA. Ann Hematol. 101(5): 1129-1132, 2022.
  12. Iemura T, Arai Y, Kitawaki T, Kanda J, Kondo T, Ueda Y, Mori T,Imada K, Yonezawa A, Yago K, Anzai N ,Kotani S, Nohgawa M, Kitano T, Itoh M, Arima N ,Moriguchi T, Watanabe M, Tsuji M,Yamashita K , Takaori-Kondo A , the Kyoto Stem Cell Transplantation Group (KSCTG). Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation. Bone Marrow Transplant. 57(5): 781-789, 2022.
  13. Hamada R, Kondo T, Harada K, Murao M, Miyasaka J, Yoshida M, Yonezawa H, Nankaku M, Arai Y, Kanda J, Takaori-Kondo A, Ikeguchi R, Matsuda S. Evaluation of indices for predicting recovery of exercise tolerance in patients surviving allogenic hematopoietic stem cell transplantation.Support Care Cancer. 30(5): 4027-4034, 2022.
  14. Tashiro Y, Kanda J, Iemura T, Kondo T, Yamashita K, Sunada M, Horie A, Takaori-Kondo A. Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia. 116(3): 453-458,Int J Hematol?. 2022.
  15. Noguchi M, Chen-Yoshikawa TF, Arai Y, Kondo T, Ohsumi A, Nakajima D, Hamaji M, Takita J, Takaori-Kondo A, Date H. Expanded indications for lung transplantation for pulmonary complications after hematopoietic stem cell transplantation. J Thorac Cardiovasc Surg. 163(4): 1549-1557, 2022.
  16. Iwasaki M, Kanda J, Arai Y, Kondo T, Ishikawa T, Ueda Y, Imada K, Akasaka T, Yonezawa A, Yago K, Nohgawa M, Anzai N, Moriguchi T, Kitano T, Itoh M, Arima N, Takeoka T, Watanabe M, Hirata H, Asagoe K, Miyatsuka I, An LM, Miyanishi M, Takaori-Kondo A. Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. Blood Adv. 6(8): 2618-2627, 2022.
  17. Wada F, Kanda J, Yoshioka S, Ishikawa T, Akasaka T, Ueda Y, Hirata H, Arai Y, Yago K, Anzai N, Watanabe M, Ikeda T, Yonezawa A, Imada K, Itoh M, Kitano T, Takeoka T, Hishizawa M, Nohgawa M, Arima N, Asagoe K, Kondo T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. Transplantation. 106(6):1279-1287, 2022.
  18. Shimizu Y, Koyasu S, Suzukida M, Izumi K, Kidera E, Shindo T, Saga T, Ono M, Takaori-Kondo A, Nakamoto Y. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. Ann Nucl Med. 36(3):319-326, 2022.
  19. Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, Yamasoba D, Gerber PP, Fatihi S, Rathore S, Zepeda SK, Papa G, Kemp SA, Ikeda T, Toyoda M, Tan TS, Kuramochi J, Mitsunaga S, Ueno T, Shirakawa K, Takaori-Kondo A, Brevini T, Mallery DL, Charles OJ; CITIID-NIHR BioResource COVID-19 Collaboration; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ecuador-COVID19 Consortium, Bowen JE, Joshi A, Walls AC, Jackson L, Martin D, Smith KGC, Bradley J, Briggs JAG, Choi J, Madissoon E, Meyer KB, Mlcochova P, Ceron-Gutierrez L, Doffinger R, Teichmann SA, Fisher AJ, Pizzuto MS, de Marco A, Corti D, Hosmillo M, Lee JH, James LC, Thukral L, Veesler D, Sigal A, Sampaziotis F, Goodfellow IG, Matheson NJ, Sato K, Gupta RK. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 603(7902): 706-714, 2022.
  20. Kazuma Y, Shirakawa K, Tashiro Y, Yamazaki H, Nomura R, Horisawa Y, Takeuchi S, Stanford E, Konishi Y, Matsui H, Matsumoto T, Tanabe F, Morishita R, Ito S, Takaori-Kondo A. ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells. Sci Rep. 12(1): 2278, 2022.
  21. Uriu K, Cárdenas P, Muñoz E, Barragan V, Kosugi Y, Shirakawa K, Takaori-Kondo A, Sato K; Ecuador-COVID19 Consortium, The Genotype to Phenotype Japan (G2P-Japan) Consortium. Characterization of the immune resistance of SARS-CoV-2 Mu variant and the robust immunity induced by Mu infection. J Infect Dis. 226(7): 1200-1203, 2022.
  22. Jo T, Yoshihara S, Hada A, Arai Y, Kitawaki T, Ikemoto J, Onomoto H, Sugiyama H, Yoshihara K, Obi N, Matsui K, Niwa N, Nakagawa Y, Kanda J, Kondo T, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Takaori-Kondo A, Nagao M. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.Transplant Cell Ther. S2666-6367(22)01229-5, 2022.
  23. Nishikori M, Takaori-Kondo A. [Epigenetic modification as a therapeutic approach for B-cell lymphoma]. Rinsho Ketsueki. 63(4): 313-321, 2022.
  24. Wada F, Kondo T, Yamamoto R, Yamagiwa T, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, Takaori-Kondo A. Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation. Bone Marrow Transplant. 2022.
  25. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 185(12): 2103-2115.e19, 2022.
  26. Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, Adachi S. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma. Blood Adv.6(14): 4216-4223, 2022.
  27. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martínez JS, Domenico D, Jädersten M, Germing U, Sanz G, van de Loosdrecht AA, Kosmider O, Follo MY, Thol FR, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Adès L, Tobiasson M, Palomo L, Della Porta MG, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellström Lindberg E, Papaemmanuil E. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 1(7), 2022.
  28. Hamada R, Asano T, Murao M, Miyasaka J, Matsushita M, Kajimoto T, Otagaki A, Nankaku M, Arai Y, Kanda J, Kondo T, Takaori-Kondo A, Ikeguchi R, Matsuda S. Intramuscular adipose tissue content predicts patient outcomes after allogeneic hematopoietic stem cell transplantation. Transplantation and CellularTherapy. 28(9): 602.e1-602.e7, 2022.
  29. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium, Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 603(7902): 700-705, 2022.
  30. Maeda R, Fujita J, Konishi Y, Kazuma Y, Yamazaki H, Anzai I, Watanabe T, Yamaguchi K, Kasai K, Nagata K, Yamaoka Y, Miyakawa K, Ryo A, Shirakawa K, Sato K, Makino F, Matsuura Y, Inoue T, Imura A, Namba K, Takaori-Kondo A. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Commun Biol. 5(1): 669, 2022.
  31. Takeda J, Yoshida K, Nakagawa MM, Nannya Y, Yoda A, Saiki R, Ochi Y, Zhao L, Okuda R, Qi X, Mori T, Kon A, Chiba K, Tanaka H, Shiraishi Y, Kuo MC, Kerr CM, Nagata Y, Morishita D, Hiramoto N, Hangaishi A, Nakazawa H, Ishiyama K, Miyano S, Chiba S, Miyazaki Y, Kitano T, Usuki K, Sezaki N, Tsurumi H, Miyawaki S, Maciejewski JP, Ishikawa T, Ohyashiki K, Ganser A, Heuser M, Thol F, Shih LY, Takaori-Kondo A, Makishima H, Ogawa S. Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia. Blood Cancer Discov. 3(5): 410-427, 2022.
  32. Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol. 13: 20406207221104584, 2022.
  33. Nagahata Y, Masuda K, Nishimura Y, Ikawa T, Kawaoka S, Kitawaki T, Nanya Y, Ogawa S, Suga H, Satou Y, Takaori-Kondo A, Kawamoto H. Tracing the evolutionary history of blood cells to the unicellular ancestor of animals. Blood. 140(24): 2611-2625, 2022.
  34. Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium, Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 185(21): 3992-4007.e16, 2022.
  35. Sugimoto N, Nakamura S, Shimizu S, Shigemasa A, Kanda J, Matsuyama N, Tanaka M, Hayashi T, Fuchizaki A, Nogawa M, Watanabe N, Okamoto S, Handa M, Sawaguchi A, Momose D, Koh KR, Tani Y, Takaori-Kondo A, Eto K. Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial. Blood Adv. 6(23): 6056-6069, 2022.
  36. Nakamura N, Arai Y, Kitawaki T, Jo T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Takaori-Kondo A. Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy. Br J Haematol. 2022.
  37. Abe T, Horisawa Y, Kikuchi O, Ozawa-Umeta H, Kishimoto A, Katsuura Y, Imaizumi A, Hashimoto T, Shirakawa K, Takaori-Kondo A, Yusa K, Asakura T, Kakeya H, Kanai M. Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin. Eur J Pharmacol. 935: 175321, 2022.
  38. Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y, Kimura I, Ito J, Yamasoba D, Nasser H, Toyoda M, Nagata K, Uriu K, Kosugi Y, Fujita S, Shofa M, Monira Begum M, Shimizu R, Oda Y, Suzuki R, Ito H, Nao N, Wang L, Tsuda M, Yoshimatsu K, Kuramochi J, Kita S, Sasaki-Tabata K, Fukuhara H, Maenaka K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Ueno T, Schreiber G, Takaori-Kondo A; Genotype to Phenotype Japan (G2P-Japan) Consortium, Shirakawa K, Sawa H, Irie T, Hashiguchi T, Takayama K, Matsuno K, Tanaka S, Ikeda T, Fukuhara T, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 30(11): 1540-1555, 2022.
  39. Hatayama Y, Yamaoka Y, Morita T, Jeremiah SS, Miyakawa K, Nishi M, Kimura Y, Mitsunaga M, Iwase T, Kimura H, Yamamoto N, Takaori-Kondo A, Hasegawa H, Ryo A. Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy. Viruses. 14(10): 2153, 2022.
  40. Makishima H, Saiki R, Nannya Y, Korotev SC, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. blood.2022018221, 2022.
  41. Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, Takaori-Kondo A. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. Sci Rep. 12(1): 18696, 2022.
  42. Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, Takaori-Kondo A. Significance of omitting day 11 mini-dose methotrexate for GVHD prophylaxis after unrelated bone marrow transplantation. Transplant Cell Ther. S2666-6367(22)01771-7, 2022.
  43. Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, Shimura Y, Ito T, Fuchida SI, Uchiyama H, Fukushima K, Yoshihara S, Hanamoto H, Tanaka H, Uoshima N, Ohta K, Yagi H, Shibayama H, Onda Y, Tanaka Y, Adachi Y, Matsuda M, Iida M, Miyoshi T, Matsui T, Takahashi R, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide. Ther Adv Hematol. 13: 20406207221142487, 2022.
  44. Kimura I, Yamasoba D, Nasser H, Zahradnik J, Kosugi Y, Wu J, Nagata K, Uriu K, Tanaka YL, Ito J, Shimizu R, Tan TS, Butlertanaka EP, Asakura H, Sadamasu K, Yoshimura K, Ueno T, Takaori-Kondo A, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Toyoda M, Shirakawa K, Irie T, Saito A, Nakagawa S, Ikeda T, Sato K. The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. iScience. 25(12): 105720, 2022.
  45. Yamaguchi K, Anzai I, Maeda R, Moriguchi M, Watanabe T, Imura A, Takaori-Kondo A, Inoue T. Structural insights into the rational design of a nanobody that binds with high affinity to the SARS-CoV-2 spike variant. J Biochem. mvac096, 2022.
  46. Sugimoto N, Kanda J, Nakamura S, Kitano T, Hishizawa M, Kondo T, Shimizu S, Shigemasa A, Hirai H, Arai Y, Minami M, Tada H, Momose D, Koh KR, Nogawa M, Watanabe N, Okamoto S, Handa M, Sawaguchi A, Matsuyama N, Tanaka M, Hayashi T, Fuchizaki A, Tani Y, Takaori-Kondo A, Eto K. iPLAT1: the first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study. Blood. 140(22): 2398-2402, 2022.
  47. Nagata K, Utsumi D, Asaka MN, Maeda R, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Yanagida Y, Kawai Y, Sato K, Yamaoka Y, Miyakawa K, Ryo A, Yasutomi Y, Imura A, Takaori-Kondo A. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice. Commun Med (Lond). 2(1): 152, 2022.